Treatment strategies involve multiple stages and management of complications. A benchmark trial reveals significant overall survival benefits and improved progression-free survival. Long-term data shows a seven-year survival advantage with manageable complications. Post-transplant therapy achieves high response rates and sustainable outcomes. Brentuximab is effective in first-line, second-line, and post-transplant settings, enhancing overall survival while reducing side effects.